YEHUD, Israel--(BUSINESS WIRE)--BioControl Medical announced today that cardiologist and surgeons at University Hospital Mannheim in Germany and at Ospedali Riuniti di Bergamo in Italy have successfully implanted the CardioFit device in the first patients to be enrolled at those sites in BioControl’s international, multi-center, open-label clinical study of the CardioFit system for the treatment of advanced congestive heart failure. BioControl (http://www.biocontrol-medical.com/) develops advanced implantable devices for the treatment of autonomic disorders.
